Screening was based on the evaluation of chemicals’ capacity to switch FGFR2 splicing from exon 9 (with the IIIc protein isoform as a product, linked with an increased invasive phenotype in prostate cancer) to exon 8 (yielding in an IIIb FGFR2 isoform, associated with decreased malignancy). Here, FGFR2 is linked to prostate carcinoma.